We have developed a spatially resolved, multi-omic map, called the Molecular Fingerprint, for diagnosing and discovering disease. Combined with artificial intelligence, this mPrint technology is the next frontier in discovery and diagnostics.
Networks of multi-omic biomarkers are required to capture the complexity of biological systems. We map heterogeneity and system level markers for discovery and translational research through services, partnerships, and strategic collaborations.
Growth and adoption of new immuno-therapies requires accurately identifying patients who will respond positively. Mapping the immune microenvironment through in-situ, multi-omic measurements is crucial for enrolling patients in clinical trials and creating companion diagnostics.
AI-Guided Treatment Plans
Cancer patients develop drug resistance to targeted therapies much like people do to antibiotics. Our mPrint Mind™ uses maps of the complex biomarker network to predict drug resistance in cancer patients and recommend treatment plans to avoid cancers reoccurring.